Published in Nat Rev Neurol on July 01, 2010
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Aquaporin 4 and neuromyelitis optica. Lancet Neurol (2012) 2.58
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol (2012) 2.45
Aquaporin water channels in the nervous system. Nat Rev Neurosci (2013) 2.10
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol (2011) 1.72
Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain (2014) 1.67
Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology (2014) 1.62
Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60
Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem (2012) 1.55
Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol (2012) 1.54
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol (2014) 1.53
Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm (2015) 1.49
Physiological roles of aquaporin-4 in brain. Physiol Rev (2013) 1.48
Aquaporin 4 molecular mimicry and implications for neuromyelitis optica. J Neuroimmunol (2013) 1.42
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS One (2011) 1.38
CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders. Clin Exp Immunol (2014) 1.30
Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol (2012) 1.28
Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology (2012) 1.25
The history of neuromyelitis optica. J Neuroinflammation (2013) 1.25
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation (2016) 1.20
Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem (2011) 1.20
Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One (2013) 1.18
The adaptive immune system in diseases of the central nervous system. J Clin Invest (2012) 1.17
Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One (2010) 1.13
Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest (2013) 1.12
Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J (2012) 1.10
Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int (2012) 1.10
Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. Glia (2012) 1.08
Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol (2012) 1.08
White matter astrocytes in health and disease. Neuroscience (2013) 1.07
Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol (2013) 1.06
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain (2012) 1.06
Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol (2012) 1.04
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation (2016) 1.01
B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol (2014) 1.01
An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays. PLoS One (2013) 1.01
Groupwise multi-atlas segmentation of the spinal cord's internal structure. Med Image Anal (2014) 0.99
'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation (2015) 0.98
Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG. Acta Neuropathol (2013) 0.95
'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. J Neuroinflammation (2015) 0.94
Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. J Neuroinflammation (2013) 0.92
Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci (2012) 0.92
C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol (2013) 0.92
Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol (2013) 0.91
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics (2016) 0.91
Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol (2012) 0.91
Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. J Autoimmun (2014) 0.91
Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica. Mol Immunol (2014) 0.90
Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. J Neuroinflammation (2014) 0.89
Applying complement therapeutics to rare diseases. Clin Immunol (2015) 0.87
Robust GM/WM segmentation of the spinal cord with iterative non-local statistical fusion. Med Image Comput Comput Assist Interv (2013) 0.86
Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation (2014) 0.85
Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. PLoS One (2012) 0.85
Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury. Acta Neuropathol Commun (2014) 0.85
On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol (2012) 0.84
The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. J Neurol (2012) 0.83
Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation (2014) 0.83
Astrocytes differentially respond to inflammatory autoimmune insults and imbalances of neural activity. Acta Neuropathol Commun (2013) 0.82
Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica. J Neurol (2012) 0.82
Acquired pathology of the pediatric spine and spinal cord. Pediatr Radiol (2015) 0.80
Tissue- and column-specific measurements from multi-parameter mapping of the human cervical spinal cord at 3 T. NMR Biomed (2013) 0.80
Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis. BMC Neurol (2013) 0.79
Olfactory dysfunction in patients with neuromyelitis optica. Mult Scler Int (2013) 0.79
Regulation of neurovascular coupling in autoimmunity to water and ion channels. Autoimmun Rev (2014) 0.78
Clinical usefulness of cell-based indirect immunofluorescence assay for the detection of aquaporin-4 antibodies in neuromyelitis optica spectrum disorder. Ann Lab Med (2012) 0.78
Light inactivation of water transport and protein-protein interactions of aquaporin-Killer Red chimeras. J Gen Physiol (2012) 0.78
Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO? Mult Scler Int (2012) 0.78
Expression and function of aquaporins in peripheral nervous system. Acta Pharmacol Sin (2011) 0.78
Immune mediated diseases and immune modulation in the neurocritical care unit. Neurotherapeutics (2012) 0.78
Homology between Klebsiella pneumoniae and human aquaporin-4: no evidence for cross-reactivity in neuromyelitis optica. A study on 114 patients. J Neurol (2010) 0.78
ZOOM or Non-ZOOM? Assessing Spinal Cord Diffusion Tensor Imaging Protocols for Multi-Centre Studies. PLoS One (2016) 0.77
Visualization of inflammation and demyelination in 2D2 transgenic mice with rodent MRI. J Neuroimmunol (2013) 0.77
Evidence for classic complement activity in neuromyelitis optica. Clin Neuropathol (2014) 0.77
Aquaporin-4 antibodies are not related to HTLV-1 associated myelopathy. PLoS One (2012) 0.77
In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. Ann Neurol (2016) 0.77
A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4. J Biol Chem (2012) 0.77
Review of Animal Models of Neuromyelitis Optica. Mult Scler Relat Disord (2012) 0.77
Follicular Helper CD4+ T Cells in Human Neuroautoimmune Diseases and Their Animal Models. Mediators Inflamm (2015) 0.76
Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol (2014) 0.76
Neurology-the next 10 years. Nat Rev Neurol (2015) 0.76
Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases. Expert Rev Neurother (2014) 0.76
Anti-aquaporin-4 antibody-positive recurrent isolated optic neuritis and primary Sjögren's syndrome. J Neurol (2012) 0.76
Classification algorithms with multi-modal data fusion could accurately distinguish neuromyelitis optica from multiple sclerosis. Neuroimage Clin (2015) 0.76
Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence. J Res Med Sci (2017) 0.75
Elevation of AQP4 and selective cytokines in experimental autoimmune encephalitis mice provides some potential biomarkers in optic neuritis and demyelinating diseases. Int J Clin Exp Pathol (2015) 0.75
Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. J Neuroinflammation (2016) 0.75
Double Roles of Macrophages in Human Neuroimmune Diseases and Their Animal Models. Mediators Inflamm (2016) 0.75
Screening feature genes of astrocytoma using a combined method of microarray gene expression profiling and bioinformatics analysis. Int J Clin Exp Med (2015) 0.75
Successful trabeculotomy in a patient with corticosteroid-induced glaucoma with anti-aquaporin 4 antibody-positive neuromyelitis optica: a case report. J Med Case Rep (2013) 0.75
Grey and White Matter Magnetisation Transfer Ratio Measurements in the Lumbosacral Enlargement: A Pilot In Vivo Study at 3T. PLoS One (2015) 0.75
Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
Immunology of neuromyelitis optica during pregnancy. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
Clinical correlations of motor and somatosensory evoked potentials in neuromyelitis optica. PLoS One (2014) 0.75
Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission. Brain Behav (2017) 0.75
White matter disease: A novel approach to treatment of neuromyelitis optica. Nat Rev Neurol (2011) 0.75
'Spinal amaurosis' (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. J Neurol (2013) 0.75
Detection of Antibodies against Human and Plant Aquaporins in Patients with Multiple Sclerosis. Autoimmune Dis (2015) 0.75
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain (2007) 4.82
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 3.83
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain (2007) 3.64
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 3.43
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 2.99
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 2.96
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol (1999) 2.69
The Molecular Biology Toolkit (MBT): a modular platform for developing molecular visualization applications. BMC Bioinformatics (2005) 2.60
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol (2006) 2.52
Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol (2008) 2.48
Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 2.41
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms. Proc Natl Acad Sci U S A (2003) 2.37
Crystal structure of human aquaporin 4 at 1.8 A and its mechanism of conductance. Proc Natl Acad Sci U S A (2009) 2.28
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun (2009) 2.20
CNS aquaporin-4 autoimmunity in children. Neurology (2008) 2.10
Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain (2007) 1.93
Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia (2009) 1.93
Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol (2009) 1.88
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol (2003) 1.79
NMO-IgG in the diagnosis of neuromyelitis optica. Neurology (2007) 1.77
Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci (2010) 1.75
The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci (2001) 1.62
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol (2008) 1.59
Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol (2008) 1.58
Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol (2009) 1.55
Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol (2008) 1.51
Neuromyelitis optica. Semin Neurol (2002) 1.48
Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med (2006) 1.46
Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry (2008) 1.41
Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler (2009) 1.41
Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun (2010) 1.40
Altered blood-brain barrier integrity in adult aquaporin-4 knockout mice. Neuroreport (2008) 1.40
NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology (2009) 1.38
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol (2004) 1.38
Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler (2007) 1.37
Live cell analysis of aquaporin-4 m1/m23 interactions and regulated orthogonal array assembly in glial cells. J Biol Chem (2009) 1.34
Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci (2002) 1.33
A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology (2009) 1.32
Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry (2006) 1.31
Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry (2010) 1.30
Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol (2009) 1.20
Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport (2009) 1.19
Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes. Mol Cell Neurosci (2006) 1.18
Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol (2007) 1.17
Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology (2004) 1.15
NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler (2008) 1.12
Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum (2010) 1.06
Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology (2009) 1.05
Activation of kainate receptors sensitizes oligodendrocytes to complement attack. J Neurosci (2006) 1.02
Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry (2009) 1.01
Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica. J Neuroimmunol (2009) 1.01
Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica. J Neuroimmunol (2009) 0.98
Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med (2006) 0.98
Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler (2009) 0.96
Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol (2009) 0.96
Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol (2006) 0.95
Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci (2010) 0.94
Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev (2009) 0.93
Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med (2010) 0.92
Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions. Mult Scler (2009) 0.91
Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry (2007) 0.88
High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology (2007) 0.88
OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol (2006) 0.85
Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection. J Neurol Sci (2008) 0.85
B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology (2010) 0.83
Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Mult Scler (2008) 0.82
Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression. J Neuroimmunol (1996) 0.82
Seroprevalence of NMO-IgG antibody in Brazilian patients with neuromyelitis optica. Arq Neuropsiquiatr (2008) 0.81
Neuromyelitis optica following CMV primo-infection. J Intern Med (2007) 0.81
Neuromyelitis optica (Devic's disease) following chicken pox. Trop Doct (1994) 0.80
Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgG. Arch Neurol (2009) 0.80
Neuromyelitis optica (Devic disease) following varicella infection. J Pediatr (1979) 0.79
AQP4-IgG immunoprecipitation assay optimization. Clin Chem (2009) 0.78
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 0.78
Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. Arq Neuropsiquiatr (2008) 0.78
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol (2005) 2.28
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol (2007) 1.74
Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol (2013) 1.69
Herpes simplex virus encephalitis despite normal cell count in the cerebrospinal fluid. Crit Care Med (2012) 1.67
Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol (2013) 1.63
Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch Neurol (2008) 1.62
Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60
In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol (2005) 1.58
T-cell homeostasis in pediatric multiple sclerosis: old cells in young patients. Neurology (2013) 1.51
Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci (2010) 1.45
Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J Immunol (2003) 1.29
The history of neuromyelitis optica. J Neuroinflammation (2013) 1.25
Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler (2011) 1.19
Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One (2013) 1.18
The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity? J Neurol Sci (2008) 1.15
GABAB receptor antibodies in paraneoplastic cerebellar ataxia. J Neuroimmunol (2013) 1.14
Acute and long-term alteration of chemokine mRNA expression after anti-viral and anti-inflammatory treatment in herpes simplex virus encephalitis. Neurosci Lett (2004) 1.12
Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum (2010) 1.06
Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. J Neuroimmunol (2009) 1.02
Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis. Blood (2007) 1.02
Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol (2011) 1.02
B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun (2011) 0.99
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Ocular outcome and frequency of neurological manifestations in patients with acute posterior multifocal placoid pigment epitheliopathy (APMPPE). J Ophthalmic Inflamm Infect (2012) 0.96
A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. J Neuroinflammation (2010) 0.94
Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro. Neurosci Lett (2002) 0.94
Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. PLoS One (2011) 0.93
Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. J Neuroinflammation (2013) 0.92
Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med (2010) 0.92
Caspr2 antibodies in limbic encephalitis with cerebellar ataxia, dyskinesias and myoclonus. J Neurol Sci (2013) 0.92
Similar sensitivity of regulatory T cells towards CD95L-mediated apoptosis in patients with multiple sclerosis and healthy individuals. J Neurol Sci (2006) 0.91
Intracerebral manifestation of an atypical monoclonal plasma cell hyperplasia depicted by MR perfusion and diffusion tensor imaging and MR spectroscopy. AJR Am J Roentgenol (2005) 0.90
The interleukin-7 receptor α chain contributes to altered homeostasis of regulatory T cells in multiple sclerosis. Eur J Immunol (2011) 0.88
Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection. J Neurol Sci (2008) 0.85
Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis. J Immunol (2013) 0.85
Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation (2014) 0.85
Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity. Clin Immunol (2009) 0.85
Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis. PLoS One (2013) 0.85
Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol (2008) 0.84
Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation (2014) 0.83
Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler (2013) 0.82
Disgust and fear recognition in paraneoplastic limbic encephalitis. Cortex (2009) 0.81
Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bands. Fluids Barriers CNS (2012) 0.80
Experimental herpes simplex virus encephalitis: inhibition of the expression of inducible nitric oxide synthase in mouse brain tissue. Neurosci Lett (2002) 0.79
Single-cell PCR analysis of the immunoglobulin heavy-chain CDR3 region for the diagnosis of leptomeningeal involvement of B-cell malignancies using standard cerebrospinal fluid cytospins. J Neurol Sci (2004) 0.79
Olfactory dysfunction in patients with neuromyelitis optica. Mult Scler Int (2013) 0.79
An early British case of neuromyelitis optica (1850). BMJ (2012) 0.77
Aquaporin-4 antibodies are not related to HTLV-1 associated myelopathy. PLoS One (2012) 0.77
Effect of storage conditions and freeze/thaw cycles on aquaporin-4 antibody (NMO-IgG) serum levels. Clin Chem Lab Med (2011) 0.77
Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology (2010) 0.75
Pavlov's Reflex before Pavlov: Early Accounts from the English, French and German Classic Literature. Eur Neurol (2017) 0.75
Flesh in the age of reason: the modern foundations of body and soul, and a dialogue by Jeremy Collier (1695). Brain (2013) 0.75
An unusual case of optic neuritis. J Neurol Sci (2011) 0.75
Administration of isoflurane-controlled dyskinetic movements caused by anti-NMDAR encephalitis. Neurology (2013) 0.75